Graduate School of Biomedical Engineering, ARC Centre of Excellence in Nanoscale Biophotonics, Faculty of Engineering, University of New South Wales, Sydney, NSW 2052, Australia; Australian Centre for NanoMedicine, University of New South Wales, Sydney, NSW 2052, Australia.
Graduate School of Biomedical Engineering, ARC Centre of Excellence in Nanoscale Biophotonics, Faculty of Engineering, University of New South Wales, Sydney, NSW 2052, Australia; Australian Centre for NanoMedicine, University of New South Wales, Sydney, NSW 2052, Australia; International Joint Research Center for Intelligent Biosensor Technology and Health, College of Chemistry, Central China Normal University, Wuhan 430079, PR China.
Trends Biotechnol. 2019 Aug;37(8):792-795. doi: 10.1016/j.tibtech.2019.04.012. Epub 2019 May 29.
Performing multiplex detection is still an elusive goal for molecular diagnostics. CRISPR/Cas-based biosensing has demonstrated potential for multiplex detection. Instead of being an insurmountable obstacle, CRISPR/Cas multiplexed biosensing is a realistic challenge with some recent successful applications. Strategic considerations are required to fully explore its potential in multiplex diagnostics.
对于分子诊断来说，实现多重检测仍然是一个难以企及的目标。基于 CRISPR/Cas 的生物传感技术已经显示出了用于多重检测的潜力。CRISPR/Cas 多重生物传感并不是无法逾越的障碍，而是一个具有现实挑战性的问题，目前已经有一些成功的应用。为了充分挖掘其在多重诊断中的潜力，需要进行策略性的考虑。
